AR077483A1 - Sal de citrato del 9e-15-(2-pirrolidin -1-il-etoxi)-7,12,25-trioxa-19-21,24-triaza-tetraciclo (18-3.1.1(2,5).1(14,18) hexacosa-1 (24),2,4,9,14,16,18 (26),20,22- nonaeno - Google Patents
Sal de citrato del 9e-15-(2-pirrolidin -1-il-etoxi)-7,12,25-trioxa-19-21,24-triaza-tetraciclo (18-3.1.1(2,5).1(14,18) hexacosa-1 (24),2,4,9,14,16,18 (26),20,22- nonaenoInfo
- Publication number
- AR077483A1 AR077483A1 ARP100102594A ARP100102594A AR077483A1 AR 077483 A1 AR077483 A1 AR 077483A1 AR P100102594 A ARP100102594 A AR P100102594A AR P100102594 A ARP100102594 A AR P100102594A AR 077483 A1 AR077483 A1 AR 077483A1
- Authority
- AR
- Argentina
- Prior art keywords
- citrate salt
- nonaeno
- hexacosa
- trioxa
- triaza
- Prior art date
Links
- 150000001860 citric acid derivatives Chemical class 0.000 title abstract 4
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22560909P | 2009-07-15 | 2009-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077483A1 true AR077483A1 (es) | 2011-08-31 |
Family
ID=42790728
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102594A AR077483A1 (es) | 2009-07-15 | 2010-07-15 | Sal de citrato del 9e-15-(2-pirrolidin -1-il-etoxi)-7,12,25-trioxa-19-21,24-triaza-tetraciclo (18-3.1.1(2,5).1(14,18) hexacosa-1 (24),2,4,9,14,16,18 (26),20,22- nonaeno |
| ARP190102219A AR114987A2 (es) | 2009-07-15 | 2019-08-05 | Sal de citrato del 9e-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-19,21,24-triaza-tetraciclo[18.3.1.1.(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaeno |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102219A AR114987A2 (es) | 2009-07-15 | 2019-08-05 | Sal de citrato del 9e-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-19,21,24-triaza-tetraciclo[18.3.1.1.(2,5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaeno |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9062074B2 (enExample) |
| EP (1) | EP2454266B1 (enExample) |
| JP (2) | JP6013911B2 (enExample) |
| CN (1) | CN102762577B (enExample) |
| AR (2) | AR077483A1 (enExample) |
| BR (1) | BR112012000750B1 (enExample) |
| CA (1) | CA2768210C (enExample) |
| DK (1) | DK2454266T3 (enExample) |
| ES (1) | ES2429525T3 (enExample) |
| HR (1) | HRP20130941T1 (enExample) |
| MX (1) | MX2012000680A (enExample) |
| PL (1) | PL2454266T3 (enExample) |
| PT (1) | PT2454266E (enExample) |
| RU (1) | RU2543721C2 (enExample) |
| SI (1) | SI2454266T1 (enExample) |
| SM (1) | SMT201300112B (enExample) |
| TW (1) | TWI537276B (enExample) |
| WO (1) | WO2011008172A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2017112748A (ru) | 2014-11-17 | 2018-12-19 | Арно Терапьютикс, Инк. | Композиции онапристона пролонгированного действия и способы |
| AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
| HK1255104A1 (zh) | 2015-12-15 | 2019-08-02 | Context Biopharma Inc. | 无定形的奥那司酮组合物及其制备方法 |
| WO2018102369A1 (en) | 2016-11-30 | 2018-06-07 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY110603A (en) * | 1993-05-27 | 1998-08-29 | Novartis Ag | Tetrahydropyran derivatives |
| US7151096B2 (en) | 2003-03-05 | 2006-12-19 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
| CN101360751B (zh) * | 2005-11-16 | 2011-09-14 | S*Bio私人有限公司 | 氧连接的嘧啶衍生物 |
-
2010
- 2010-07-14 BR BR112012000750-5A patent/BR112012000750B1/pt not_active IP Right Cessation
- 2010-07-14 JP JP2012520571A patent/JP6013911B2/ja active Active
- 2010-07-14 MX MX2012000680A patent/MX2012000680A/es active IP Right Grant
- 2010-07-14 CA CA2768210A patent/CA2768210C/en active Active
- 2010-07-14 EP EP10737645.1A patent/EP2454266B1/en active Active
- 2010-07-14 WO PCT/SG2010/000265 patent/WO2011008172A1/en not_active Ceased
- 2010-07-14 PT PT107376451T patent/PT2454266E/pt unknown
- 2010-07-14 US US13/384,139 patent/US9062074B2/en active Active
- 2010-07-14 CN CN201080032627.5A patent/CN102762577B/zh active Active
- 2010-07-14 RU RU2012105044/04A patent/RU2543721C2/ru active
- 2010-07-14 PL PL10737645T patent/PL2454266T3/pl unknown
- 2010-07-14 HR HRP20130941AT patent/HRP20130941T1/hr unknown
- 2010-07-14 SI SI201030347T patent/SI2454266T1/sl unknown
- 2010-07-14 ES ES10737645T patent/ES2429525T3/es active Active
- 2010-07-14 DK DK10737645.1T patent/DK2454266T3/da active
- 2010-07-15 TW TW099123331A patent/TWI537276B/zh active
- 2010-07-15 AR ARP100102594A patent/AR077483A1/es not_active Application Discontinuation
-
2013
- 2013-10-04 SM SM201300112T patent/SMT201300112B/xx unknown
-
2015
- 2015-05-07 JP JP2015094972A patent/JP2015164941A/ja active Pending
-
2019
- 2019-08-05 AR ARP190102219A patent/AR114987A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2429525T3 (es) | 2013-11-15 |
| HRP20130941T1 (hr) | 2013-11-08 |
| BR112012000750A2 (pt) | 2016-08-09 |
| PT2454266E (pt) | 2013-10-10 |
| DK2454266T3 (da) | 2013-09-08 |
| PL2454266T3 (pl) | 2014-01-31 |
| EP2454266B1 (en) | 2013-07-10 |
| BR112012000750A8 (pt) | 2018-02-06 |
| RU2543721C2 (ru) | 2015-03-10 |
| HK1178159A1 (en) | 2013-09-06 |
| MX2012000680A (es) | 2012-02-28 |
| BR112012000750B1 (pt) | 2021-05-25 |
| CA2768210A1 (en) | 2011-01-20 |
| US20120196876A1 (en) | 2012-08-02 |
| WO2011008172A1 (en) | 2011-01-20 |
| JP6013911B2 (ja) | 2016-10-25 |
| EP2454266A1 (en) | 2012-05-23 |
| CA2768210C (en) | 2017-08-15 |
| TW201107336A (en) | 2011-03-01 |
| SI2454266T1 (sl) | 2013-10-30 |
| SMT201300112B (it) | 2013-11-08 |
| AR114987A2 (es) | 2020-11-11 |
| JP2015164941A (ja) | 2015-09-17 |
| CN102762577A (zh) | 2012-10-31 |
| US9062074B2 (en) | 2015-06-23 |
| JP2012533539A (ja) | 2012-12-27 |
| TWI537276B (zh) | 2016-06-11 |
| CN102762577B (zh) | 2015-01-07 |
| RU2012105044A (ru) | 2013-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2649340T3 (es) | Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer | |
| BR112015008365A2 (pt) | composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente | |
| WO2015095227A3 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| GB201106743D0 (en) | Novel compounds | |
| GB201106750D0 (en) | Novel compounds | |
| AR088694A1 (es) | Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| EA201490559A1 (ru) | Композиция для лечения свища | |
| UA111717C2 (uk) | Склад для перорального введення і ліпофільні солі метилналтрексону | |
| AR088622A1 (es) | 18-METIL-6,7-METILEN-3-OXO-17-PREGN-4-EN-21,17b-CARBOLACTONA, PREPARADOS FARMACEUTICOS QUE CONTIENEN LOS COMPUESTOS MENCIONADOS Y SU USO EN LA TERAPIA DE LA ENDOMETRIOSIS | |
| PH12015501088A1 (en) | Dimeric compounds | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
| MX340574B (es) | Imidazo pirazinas. | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| CL2008000629A1 (es) | Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer. | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| BR112016005317A2 (pt) | derivados de quinazolina e seu uso como inibidores de dna metiltransferase | |
| CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
| CY1117541T1 (el) | Αντικαρκινικες στεροειδεις λακτονες μη κορεσμενες στη θεση 7(8) | |
| CL2014001959A1 (es) | Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer. | |
| HK1220443A1 (zh) | 用作止痛药的全氢喹喔啉衍生物 | |
| BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |